Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events – pneumonia · adults after cardiopulmonary resuscitation
The intervention showed no clear difference in adverse events – pneumonia (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events – arrhythmia · adults after cardiopulmonary resuscitation
The intervention may leads to higher adverse events – arrhythmia (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events – hypokalaemia · adults after cardiopulmonary resuscitation
It is very uncertain whether the intervention changes adverse events – hypokalaemia (very low certainty).
1 finding from 1 review
Adverse events (any type) and safety of sealant · Children and/or adults with permanent or primary teeth, vital (sensitive) pulps, and cavitated or dentine carious lesions conventionally…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events Number of events · participants with acute or subacute low‐back pain
It is very uncertain whether back school changes adverse events Number of events compared with joint manipulation (very low certainty).
1 finding from 1 review
Adverse events Number of events · participants with acute or subacute low‐back pain
It is very uncertain whether back school changes adverse events Number of events compared with combined myofascial therapy and joint manipulation (very low certainty).
1 finding from 1 review
Major adverse events · adult patients presenting with symptoms of ureteral stone disease
Alpha‐blockers showed no clear difference in major adverse events compared with standard therapy (low certainty).
1 finding from 1 review
Major adverse events · adult patients presenting with symptoms of ureteral stone disease
Alpha‐blockers probably leads to higher major adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Number withdrawn due to adverse events · health problem or population
Summary of findings table ‐ Cannabis may leads to higher withdrawn due to adverse events ( compared with placebo (low certainty).
1 finding from 1 review
Adverse events: abscess formation · participants undergoing clean, clean‐contaminated, contaminated or dirty surgical procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: gingival bleeding · Children with decayed primary molar teeth
Preformed crown (any material; conventional technique or Hall… showed no clear difference in adverse events: gingival bleeding compared with filling (any material; with or without complete carious tissue…; GRADE not reported.
2 findings from 1 review
Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Serious adverse events (at 54 weeks) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 750 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Benralizumab 10 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Benralizumab 30 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review